Serelaxin as a Novel Treatment for Acute Heart Failure: Results of the RELAX-AHF Trial

Article Figures & Data

Figures

  • Figure 1.

    Dyspnea Relief (VAS AUC).

    AUC=area under the curve; VAS=visual analog scale.
  • Figure 2.

    Cardiovascular Death Through Day 180.

    CV=cardiovascular; ITT=intention-to-treat; KM=Kaplan-Meier; NNT=number needed to treat.
  • Figure 3.

    All-Cause Death Through Day 180.

    KM=Kaplan-Meier; ITT=intention-to-treat; NNT=number needed to treat. Figures 1 through 3 reprinted from The Lancet [Epub ahead of print Nov. 7, 2012], Teerlink JR et al. Serelaxin, Recombinant Human Relaxin-2, for Treatment of Acute Heart Failure (RELAX-AHF): A Randomised, Placebo-Controlled Trial.Copyright 2012, with permission from Elsevier.